Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1Diabetes Mellitus, Type 2 1

Interventions

Blood Specimen Collection 53Surveys and Questionnaires 30Drug Therapy 27Immunotherapy 25Surgical Procedures, Operative 22Carboplatin 22Nivolumab 21Immune Checkpoint Inhibitors 20pembrolizumab 18osimertinib 18atezolizumab 17Observation 17Radiotherapy 16Bevacizumab 15Cisplatin 14Afatinib 14Specimen Handling 13Gene Expression Profiling 13Erlotinib Hydrochloride 13lorlatinib 12Pemetrexed 12Magnetic Resonance Spectroscopy 11Ipilimumab 11Immunohistochemistry 11Biopsy 11durvalumab 10alectinib 10Paclitaxel 10Bronchoscopy 10Tomography, X-Ray Computed 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Dipeptidyl-Peptidase IV Inhibitors × Thoracic × Clear all
NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡